[go: up one dir, main page]

MX2019010974A - Compuestos y metodos para la reduccion celular especifica de tumor. - Google Patents

Compuestos y metodos para la reduccion celular especifica de tumor.

Info

Publication number
MX2019010974A
MX2019010974A MX2019010974A MX2019010974A MX2019010974A MX 2019010974 A MX2019010974 A MX 2019010974A MX 2019010974 A MX2019010974 A MX 2019010974A MX 2019010974 A MX2019010974 A MX 2019010974A MX 2019010974 A MX2019010974 A MX 2019010974A
Authority
MX
Mexico
Prior art keywords
specific cell
cell depletion
tumour specific
optimized anti
tumor
Prior art date
Application number
MX2019010974A
Other languages
English (en)
Inventor
Pascal Merchiers
Anne Goubier
Karl Peggs
Sergio Quezada
Josephine Salimu
Corzo Beatriz Goyenechea
Kevin Moulder
Isabelle Salomon
Vargas Frederick Arce
Original Assignee
Tusk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1710879.6A external-priority patent/GB201710879D0/en
Priority claimed from GBGB1714429.6A external-priority patent/GB201714429D0/en
Application filed by Tusk Therapeutics Ltd filed Critical Tusk Therapeutics Ltd
Publication of MX2019010974A publication Critical patent/MX2019010974A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se encuentra en el campo de la inmunoterapia contra el cáncer y se refiere a un método para tratar el cáncer, que incluye un método para tratar tumores sólidos, en donde el método implica el uso de un anticuerpo anti-CD25 en un sujeto que no inhibe sustancialmente la unión de Interleucina-2 (IL-2) en CD25 o la señalización de IL-2 a través de CD25.
MX2019010974A 2017-03-17 2018-03-13 Compuestos y metodos para la reduccion celular especifica de tumor. MX2019010974A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17161717 2017-03-17
GBGB1710879.6A GB201710879D0 (en) 2017-07-06 2017-07-06 Methods and compounds for tumour-specific cell depletion
GBGB1714429.6A GB201714429D0 (en) 2017-09-07 2017-09-07 Compounds and methods for tumour-specific cell depletion
PCT/EP2018/056312 WO2018167104A1 (en) 2017-03-17 2018-03-13 Fc-optimized anti-cd25 for tumour specific cell depletion

Publications (1)

Publication Number Publication Date
MX2019010974A true MX2019010974A (es) 2020-08-03

Family

ID=61655786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010974A MX2019010974A (es) 2017-03-17 2018-03-13 Compuestos y metodos para la reduccion celular especifica de tumor.

Country Status (26)

Country Link
US (1) US11879014B2 (es)
EP (1) EP3596123B1 (es)
JP (2) JP2020514363A (es)
KR (1) KR20190130137A (es)
CN (1) CN110869388B (es)
AU (1) AU2018233976B2 (es)
BR (1) BR112019017017A2 (es)
CA (1) CA3056506A1 (es)
CL (1) CL2019002624A1 (es)
CR (1) CR20190477A (es)
DK (1) DK3596123T3 (es)
ES (1) ES2975063T3 (es)
FI (1) FI3596123T3 (es)
HR (1) HRP20240469T1 (es)
HU (1) HUE065999T2 (es)
IL (1) IL269081A (es)
LT (1) LT3596123T (es)
MX (1) MX2019010974A (es)
MY (1) MY208220A (es)
NZ (1) NZ756984A (es)
PE (1) PE20191812A1 (es)
PL (1) PL3596123T3 (es)
RS (1) RS65351B1 (es)
SG (1) SG11201908578YA (es)
SI (1) SI3596123T1 (es)
WO (1) WO2018167104A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
JP7510348B2 (ja) * 2018-03-13 2024-07-03 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
WO2020102603A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Engineered cd25 polypeptides and uses thereof
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
US20220251232A1 (en) * 2019-05-20 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
PL3932949T3 (pl) * 2019-06-10 2025-11-24 Shandong Boan Biotechnology Co., Ltd. Przeciwciało anty-cd25 i jego zastosowanie
MX2022012721A (es) 2020-04-10 2023-01-16 Rakuten Medical Inc Compuestos de colorantes basados en ftalocianina, conjugados y metodos de uso de los mismos.
JP2023525060A (ja) * 2020-05-14 2023-06-14 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
WO2022106663A1 (en) * 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022106665A1 (en) * 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
AU2022228640A1 (en) 2021-03-01 2023-07-20 F. Hoffmann-La Roche Ag Novel biomarkers and uses thereof
CN117916266A (zh) 2021-09-02 2024-04-19 弗哈夫曼拉罗切有限公司 用于治疗aml的抗体
JP2025514847A (ja) 2022-04-26 2025-05-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法
CN115181182B (zh) * 2022-06-13 2024-03-29 南京融捷康生物科技有限公司 一种人源化的抗cd25的单域抗体及其应用
JP2025525451A (ja) * 2022-06-30 2025-08-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｄ２５特異的抗体およびその使用
CN119451978A (zh) 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN118240080A (zh) * 2022-12-22 2024-06-25 深圳市福元生物科技有限公司 一种cd25单域抗体、人源化抗体、及制备方法
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
CN120314588B (zh) * 2025-05-21 2025-10-17 成都蓉生药业有限责任公司 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
EP1578397B1 (en) 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
GEP20125612B (en) 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
RU2391401C2 (ru) 2008-02-12 2010-06-10 Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
PL2480671T3 (pl) 2009-09-22 2015-12-31 Probiogen Ag Proces produkcji cząsteczek zawierających specjalne struktury glikanowe
SI2516457T1 (en) * 2009-12-21 2018-08-31 Regeneron Pharmaceuticals, Inc. MUSHROOM WITH HUMANIZED FC GAMES R
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
MX349662B (es) 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
AU2014232416B2 (en) * 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
CN105377892A (zh) 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
US20150010538A1 (en) 2013-03-15 2015-01-08 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3020204A1 (en) 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
MX2020008769A (es) 2018-03-13 2020-10-08 Tusk Therapeutics Ltd Agentes anticuerpos anti-cd25.

Also Published As

Publication number Publication date
NZ756984A (en) 2025-08-29
JP2024050684A (ja) 2024-04-10
EP3596123B1 (en) 2024-01-10
CN110869388B (zh) 2024-09-20
PE20191812A1 (es) 2019-12-26
HRP20240469T1 (hr) 2024-07-19
FI3596123T3 (fi) 2024-04-17
BR112019017017A2 (pt) 2020-04-14
US11879014B2 (en) 2024-01-23
HUE065999T2 (hu) 2024-06-28
PL3596123T3 (pl) 2024-06-24
ES2975063T3 (es) 2024-07-03
CN110869388A (zh) 2020-03-06
LT3596123T (lt) 2024-03-25
WO2018167104A1 (en) 2018-09-20
IL269081A (en) 2019-11-28
EP3596123A1 (en) 2020-01-22
JP2020514363A (ja) 2020-05-21
CL2019002624A1 (es) 2020-04-03
RS65351B1 (sr) 2024-04-30
US20200010554A1 (en) 2020-01-09
MY208220A (en) 2025-04-24
CA3056506A1 (en) 2018-09-20
AU2018233976A1 (en) 2019-10-31
SI3596123T1 (sl) 2024-05-31
CR20190477A (es) 2020-01-07
KR20190130137A (ko) 2019-11-21
AU2018233976B2 (en) 2025-03-20
DK3596123T3 (da) 2024-02-26
SG11201908578YA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
NZ756984A (en) Fc-optimized anti-cd25 for tumour specific cell depletion
MX2018012319A (es) Anticuerpos biespecificos contra el receptor de fc gamma cd25 para la reduccion de celulas especificas de tumores.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
PH12020550203A1 (en) Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
BR112019014615A2 (pt) Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
NZ737418A (en) Anti-ntb-a antibodies and related compositions and methods
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
EP3964527A3 (en) Combination therapy for cancer
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
TN2017000470A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MX2017012939A (es) Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
EP3649153B8 (en) Fc optimised anti-cd25 antibodies for tumor specific cell depletion
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion